These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1434216)

  • 1. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
    Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Colony-stimulating factor activity in malignant pleural effusions and its augmentation by local administration of interleukin 2].
    Nakanishi M; Sone S; Ogura T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Jul; 29(7):824-8. PubMed ID: 1920977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
    Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
    Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion].
    Suzuki H
    Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1922-31. PubMed ID: 2608022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Mao G; Gao Z; Wang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new approach to the treatment of malignant effusion.
    Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
    Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Li DJ
    Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
    Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
    Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
    Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
    Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.
    Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA
    Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma].
    Hazama S; Oka M; Yoshino S; Iizuka N; Wadamori K; Yamamoto K; Hirazawa K; Wang F; Ogura Y; Masaki Y
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1595-7. PubMed ID: 7574768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients.
    Takeuchi E; Yanagawa H; Suzuki Y; Shinkawa K; Bando H; Sone S
    Cytokine; 2001 Jan; 13(2):119-23. PubMed ID: 11145853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
    Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
    Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.